Developmental and Epileptic Encephalopathies Market: How Gene Therapies, RNA-Based Medicines, & Precision Diagnostics Reshape Care, Thelansis Reports

Developmental and Epileptic Encephalopathies (DEEs), a group of severe, early-onset neurological conditions including Dravet syndrome, CDKL5 Deficiency Disorder, Lennox-Gastaut syndrome, and SCN2A-related and Angelman-related encephalopathies, remain one of the most challenging and fastest-evolving corners of rare neurology.

A newly published report by Thelansis, "Developmental and Epileptic Encephalopathies (DEE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast (2026-2036)," takes a close look at how the field is shifting from broad seizure control toward genetically targeted, disease-modifying care across the 8 major markets: the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and China.

Executive Summary

DEEs place an enormous burden on patients, families, and caregivers, marked by drug-resistant seizures alongside developmental, cognitive, and behavioral impairment. For years, treatment options were largely limited to broad-spectrum anti-seizure medications used off-label. That picture is changing fast:
• Regulatory milestones such as ZTALMY (ganaxolone) for CDKL5 Deficiency Disorder and FINTEPLA (fenfluramine) for Dravet syndrome and Lennox-Gastaut syndrome have proven that syndrome-specific approval pathways are achievable
• A wave of RNA-based and gene-targeted therapies is now advancing through late-stage trials, aiming to address the underlying genetic drivers rather than just symptoms
• Genetic testing is being diagnosed and adopted earlier, shortening the historically long diagnostic odyssey many families face

The report unpacks these shifts country by country, pairing epidemiological modeling with a clear-eyed view of where commercial opportunity is heading.

Request a free sample of Thelansis' Developmental and Epileptic Encephalopathies (DEEs) Market Outlook and Forecast Report to secure the complete 2026-2036 forecast, exclusive KOL insights, and competitive pipeline data across the 8 Major Markets: https://thelansis.com/reports/developmental-and-epileptic-encephalopathies-dees-market-outlook-forecast-2026-to-2036/

Key Emerging Players

The competitive field is thinning out some long-standing candidates while advancing several front-runners:
• Stoke Therapeutics - zorevunersen (STK-001), an antisense oligonucleotide designed to restore healthy SCN1A protein expression in Dravet syndrome, now enrolling in the pivotal Phase 3 EMPEROR study
• Lundbeck - bexicaserin, a 5-HT2C-targeting oral therapy for drug-resistant DEEs including Dravet syndrome, in Phase 3 (DEEp SEA study)
• Oak Hill Bio - rugonersen, positioned for a potential pivotal Phase 3 start in Angelman syndrome following encouraging Phase 1 TANGELO data
• Encoded Therapeutics - ETX101, a one-time AAV9-based gene regulation therapy in early-phase development for SCN1A-related Dravet syndrome
• Epygenix Therapeutics - clemizole (EPX-100), now in Phase 3 for Dravet syndrome
• Established players including Marinus Pharmaceuticals, UCB, Jazz Pharmaceuticals, and Zogenix/UCB continue to defend and expand their footprint through label extensions and lifecycle strategies

The report profiles these companies alongside their trial designs, mechanisms, and expected timelines to approval across all 8MM.

Request a sample report for an in-depth analysis of key emerging players, pipeline staging, and mechanisms of action in Developmental and Epileptic Encephalopathies: https://thelansis.com/reports/developmental-and-epileptic-encephalopathies-dees-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dees_mo

Key Current Therapies or Standard of Care

Despite the pipeline momentum, day-to-day management still leans heavily on a mix of older and newer anti-seizure medications:
• Broad-spectrum agents such as valproate, clobazam, and levetiracetam remain first-line in many DEE subtypes
• FINTEPLA (fenfluramine) and EPIDIOLEX (cannabidiol) have become important add-on options for Dravet syndrome and Lennox-Gastaut syndrome
• ZTALMY (ganaxolone) stands as the only FDA-approved therapy specifically for CDKL5 Deficiency Disorder, giving it a strong, largely uncontested position in that niche
• Ktogenic dietary therapy and vagus nerve stimulation continue to serve as adjunctive options for refractory cases where pharmacotherapy alone falls short

The report benchmarks utilization patterns and prescribing trends for each therapy across the 8MM, highlighting where uptake is accelerating and where gaps in access persist.

Key Market Drivers/Trends

Several forces are converging to push the DEE space into a higher-growth phase:
• A genuine pivot from symptomatic control to precision, mechanism-based treatment, with ASOs, gene therapies, and small molecules targeting specific genetic subtypes (SCN1A, SCN2A, CDKL5, and beyond)
• Wider, faster genetic testing at diagnosis, which is expanding the identified and treatable patient pool • Growing regulatory openness to syndrome-specific approvals and orphan designations, shortening timelines for rare pediatric epilepsies
• Not every program is succeeding, soticlestat's Phase 3 setback in Dravet syndrome and Lennox-Gastaut syndrome this year is a reminder that this remains a scientifically demanding space, even as it reshapes the competitive order
• Active patient advocacy groups and epilepsy foundations are increasingly shaping trial design and access conversations alongside regulators

Translate these macro drivers into a competitive advantage. Request the Thelansis Developmental and Epileptic Encephalopathies (DEEs) sample report to unlock granular pipeline analysis, deal tracking, and market forecasts: https://thelansis.com/reports/developmental-and-epileptic-encephalopathies-dees-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dees_mo

Key Unmet Need & KOL Expectations
Even with real progress, DEEs remain far from solved. Clinicians and caregivers consistently point to the same gaps:
• Most DEE subtypes still have no approved disease-modifying option, leaving families reliant on off-label, trial-and-error regimens
• Seizure control alone isn't enough, KOLs increasingly stress that cognitive, behavioral, and quality-of-life outcomes need to be built into how new therapies are evaluated and valued
• Cost and access remain real barriers, particularly for gene therapies and ASOs that carry high price tags and complex administration requirements
• There's a clear call for better natural history data and biomarkers to speed up trial design and regulatory review for these small, heterogeneous patient populations
The report captures these perspectives directly, translating clinical expectations into what they mean for market entry and positioning.

Commercial Opportunity
For biopharma and investment stakeholders, DEEs represent a rare combination: high unmet need, growing diagnostic identification, and a maturing regulatory pathway for rare pediatric neurology assets.
• Syndrome-specific launches (following the ZTALMY and FINTEPLA playbook) continue to show that focused, well-positioned assets can capture durable market share with limited direct competition
• China and Japan represent significant, still-underpenetrated growth opportunities as diagnostic infrastructure and reimbursement pathways continue to mature
• Disease-modifying candidates nearing pivotal readouts (zorevunersen, bexicaserin, rugonersen) could meaningfully expand the addressable market beyond current seizure-focused therapies
• Companies that pair strong clinical data with caregiver- and KOL-informed value propositions are best positioned to lead as the field shifts toward precision care

The full report offers detailed epidemiological forecasts, competitive benchmarking, and market sizing across the US, EU4, UK, Japan, and China built to support strategic planning, licensing, and investment decisions in this space.

Ready for the complete picture? Get Your DEE Market Outlook and Forecast Report Today. Request Now: https://thelansis.com/reports/developmental-and-epileptic-encephalopathies-dees-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dees_mo

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.